Captopril-associated cholestasis complicating the management of pancreatic cancer.

M. A. Kocab, D. Coppola, S. Hiotis, R. C. Karl, J. S. Barthel

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Cholestatic jaundice is a rare complication associated with the use of the angiotensin -converting enzyme inhibitor captopril. The severity of the disease may range from cholestasis on liver histology to overt fulminant hepatic failure. This diagnosis is seldom considered in patients with pancreatic or biliary tract malignancy. We present a patient with unresectable adenocarcinoma of the pancreas whose jaundice decreased slowly over many weeks despite establishment of adequate endoscopic biliary drainage. The presence of captopril-associated cholestasis confounded confirmation of adequate biliary drainage. The absence of observed hepatic bile secretion at duodenoscopy, as seen in this patient, is a previously unreported endoscopic feature of this syndrome.

Original languageEnglish
Pages (from-to)681
Number of pages1
JournalSurgical Endoscopy and Other Interventional Techniques
Issue number7
StatePublished - Jul 2000
Externally publishedYes


Dive into the research topics of 'Captopril-associated cholestasis complicating the management of pancreatic cancer.'. Together they form a unique fingerprint.

Cite this